OpenAI CEO Sam Altman said he would grant "employee level" access to outside researchers to evaluate AI safety. The pilot ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
A third quarter recap from Najat Khan, Ph.D., Chief Executive Officer and President of Recursion, including encouraging REC-1245 monotherapy data, as well as a presentation REC-4481 data from the ...
Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver. Today, we'll share the new FAP data ...
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
Git security updates fix six flaws, including one that lets malicious repositories execute attacker code during recursive cloning.
A $10 million Sanofi milestone drove revenue 258% higher year over year, beating expectations and showing the AI platform converts into partner cash. October's raise pushed pro forma cash near ...
Management is implementing a disciplined capital allocation strategy, lowering 2026 cash operating expense guidance to $375 million and projecting a further reduction to under $360 million in 2027.
Recursion Pharmaceuticals, Inc. ( RXRX ), a clinical-stage company pioneering AI-enabled drug discovery and development, reported third-quarter results ended September 30, 2026, reflecting a narrower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results